VANCOUVER, Feb. 13, 2019 /CNW/ - Sirona Biochem Corp.
(TSX-V: SBM) (FSE: ZSB) (the "Company") announces that it
has advanced the commercial development and IP protection of its
novel skin lightening agent TFC-1067.
As part of Sirona's continued commercialization efforts, the
scientific team has engaged consultant, Gael Boutry (Global Beauty Consulting) to create
the next generation formulation of TFC-1067. Sirona's first
formulation was a simplified design for use in its current clinical
trial. The primary objective was to demonstrate the efficacy of
TFC-1067 without any enhancers.
The new formulation has been developed in order to maximize the
efficacy of TFC-1067 through the synergic effect of different
actives. The target is to combine a faster effect by acting on cell
renewal, and a stronger depigmenting/lightening effect by acting on
different pathways. TFC-1067 has shown scientifically to safely
inhibit new pigmentation formation in the melanocyte skin cells by
inhibiting a key enzyme called tyrosinase. Stimulating cell renewal
through exfoliation of the most superficial skin layer will shorten
the normal skin renewal cycle with a goal to obtain visible results
quicker. Other approaches on the melanocyte's development could
provide a synergic effect with TFC-1067 and lead to stronger
efficacy.
The process of optimally formulating TFC-1067 is a necessary
step prior to a commercial launch of this type of active. The
formulation will undergo testing to demonstrate stability as well
as human patch testing to demonstrate that it is a non-irritant.
While waiting for the results of the clinical trial now underway,
the team is simultaneously working on these steps with the goal to
optimize the current product's commercial value while also
shortening the time to commercialization.
Sirona has also continued to expand patent coverage of TFC-1067
and the seven other compounds which make up the family of skin
lightening agents.
One filed patent has entered the European Phase and the company
has now formally selected key European countries to specifically
patent protect our family of skin lighteners. Another patent has
entered the PCT Phase where key countries have been selected as the
major world markets. Sirona currently has 9 patents filed in
multiple key markets to maximize the commercial value of our novel
compounds and wide range of therapeutic and cosmetic applications.
Sirona has taken great care to patent not only its key discoveries
but also the related family of compounds to help protect its IP
from competitors.
"We are excited to be able to continually innovate while
aggressively protecting our innovations through strong patents.
Having our own dedicated lab with a successful scientific team and
having the services of a leading biotechnology patent firm
Regimbeau of Paris has enabled us
to steadily grow the commercial value of our technology." reports
Dr Howard Verrico CEO. "We are also fortunate to have world class
consultants like Gael Boutry
providing necessary specialized expertise as well as the ongoing
financial support of the French government and European Union while
we work towards becoming financially self-sufficient. We feel
well-prepared to enter anticipated licensing discussions at the
completion of our current skin lightening clinical trial as a next
step towards being part of the 20 Billion
USD global skin lightening market1".
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery
company with a proprietary platform technology. Sirona specializes
in stabilizing carbohydrate molecules with the goal of improving
efficacy and safety. New compounds are patented for maximum revenue
potential.
Sirona's compounds are licensed to leading companies around the
world in return for licensing fees, milestone fees and ongoing
royalty payments. Sirona's laboratory, TFChem, is in France and is the recipient of multiple French
national scientific awards and European Union and French government
grants. For more information, please
visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Sirona Biochem cautions you that statements included in this
press release that are not a description of historical facts may be
forward-looking statements. Forward-looking statements are only
predictions based upon current expectations and involve known and
unknown risks and uncertainties. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of release of the relevant information, unless
explicitly stated otherwise. Actual results, performance or
achievement could differ materially from those expressed in, or
implied by, Sirona Biochem's forward-looking statements due to the
risks and uncertainties inherent in Sirona Biochem's business
including, without limitation, statements about: the progress and
timing of its clinical trials; difficulties or delays in
development, testing, obtaining regulatory approval, producing and
marketing its products; unexpected adverse side effects or
inadequate therapeutic efficacy of its products that could delay or
prevent product development or commercialization; the scope and
validity of patent protection for its products; competition from
other pharmaceutical or biotechnology companies; and its ability to
obtain additional financing to support its operations. Sirona
Biochem does not assume any obligation to update any
forward-looking statements except as required by law.
_____________________________________
|
1 Fact.MR (July 2018) Retrieved from:
https://globenewswire.com/news-release/2018/07/10/1535161/0/en/Key-Insights-on-Skin-Lightening-Products-Market-through-2022-by-Fact-MR.html
|
SOURCE Sirona Biochem Corp.